FDA Gives NewcelX Clear Path for NCEL-101 Clinical Trials in Type 1 Diabetes
NCEL has more than doubled off its 52-week low of $1.83.
Summary
NewcelX announced a successful FDA Pre-IND meeting for its lead Type 1 Diabetes candidate, NCEL-101, receiving clear guidance to advance toward clinical trials. This positive feedback on the development strategy, CMC processes, and preclinical program significantly de-risks the regulatory pathway. The news follows the company's Pre-IND submission in May and comes amidst recent 'going concern' warnings and shareholder approval for dilutive share issuance. This regulatory clarity is critical for NewcelX's future and its collaboration with Eledon Pharmaceuticals on the combination therapy.
At the time of this announcement, NCEL was trading at $3.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.6M. The 52-week trading range was $1.83 to $302.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.